Uterine Sarcoma and Carcinosarcoma: A Two-Center Experience in Iran

  • سال انتشار: 1403
  • محل انتشار: مجله سرطان خاورمیانه، دوره: 15، شماره: 3
  • کد COI اختصاصی: JR_MISJ-15-3_008
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 144
دانلود فایل این مقاله

نویسندگان

Sare Hosseini

Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Soudeh Arastouei

Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Monavar Afzalaghaei

Department of Epidemiology and Biostatistics, School of Health, Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Elham Zarei

Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Seyed Parham Ahmadi

Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

چکیده

Background: Uterine sarcomas (US) represent a rare and heterogeneous spectrum of tumors characterized by diverse clinical behaviors and tumor responses. This study aims to assess patient and tumor characteristics and oncologic outcomes.Method: This historical cohort study encompassed all patients with histologically confirmed diagnoses of the US who were referred to two oncology centers affiliated with Mashhad University of Medical Sciences (Iran) between March ۲۰۱۱ and April ۲۰۲۰. Data analyses were conducted using STATA version ۱۴.۰۲. Survival estimation was carried out utilizing the Kaplan-Meier method. The significance level was established at ۰.۰۵.Results: A total of ۳۳ patients were included in this study, comprising ۲۳ with US and ۱۰ with carcinosarcoma (CS). The mean age was ۴۹.۳ years for CS and ۶۲.۴ years for US (P = ۰.۰۰۰۱). Nearly all patients were overweight, with a mean body mass index of ۲۷.۱ (confidence interval: ۲۵.۶-۲۸.۷). The majority of patients were diagnosed at an early stage. The Federation of Gynecology and Obstetrics (FIGO) stage, patient's anemia, and surgical resection were identified as significant prognostic factors. The median overall survival was ۵۰.۸۸ ± ۵.۷ months. The survival rates at ۲, ۳, and ۵ years were ۷۵%, ۵۶%, and ۴۱%, respectively. No significant difference was observed between CS and US regarding overall and disease-free survival.Conclusion: Despite the typical early-stage diagnosis for US patients, the ۵-year survival rate remains low. This study underscores the pivotal role of FIGO stage, tumor size, and surgical resection as vital prognostic factors for survival.

کلیدواژه ها

Uterine Neoplasms, Carcinosarcoma, Survival analysis, Prognosis

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.